<code id='799D9AC153'></code><style id='799D9AC153'></style>
    • <acronym id='799D9AC153'></acronym>
      <center id='799D9AC153'><center id='799D9AC153'><tfoot id='799D9AC153'></tfoot></center><abbr id='799D9AC153'><dir id='799D9AC153'><tfoot id='799D9AC153'></tfoot><noframes id='799D9AC153'>

    • <optgroup id='799D9AC153'><strike id='799D9AC153'><sup id='799D9AC153'></sup></strike><code id='799D9AC153'></code></optgroup>
        1. <b id='799D9AC153'><label id='799D9AC153'><select id='799D9AC153'><dt id='799D9AC153'><span id='799D9AC153'></span></dt></select></label></b><u id='799D9AC153'></u>
          <i id='799D9AC153'><strike id='799D9AC153'><tt id='799D9AC153'><pre id='799D9AC153'></pre></tt></strike></i>

          fashion

          fashion

          author:knowledge    Page View:886
          Sammy Kimball for STAT

          Why do CEOs talk like that? Do biotech stock tips make good gifts? And what do Anthony Fauci and Stéphane Bancel have in common?

          We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. First, we discuss why Wall Street was less than convinced by Biogen’s attempt to assuage concerns about its credibility. Then we explain an insider trading scandal that bridges biotech and elite-level soccer, the latest concerns over Wegovy, and the rest of the week’s news in the life sciences. We also break some bittersweet news, with the help of some headline names from around biotech.

          advertisement

          For more on what we cover, here’s the Biogen news; here are the charges against Joe Lewis; here’s the latest on Wegovy; here’s where you can find episodes of Color Code; and here’s where you can subscribe to the First Opinion Podcast.

          Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

          And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

          knowledge

          Medicare details structure of new drug price negotiation program
          Medicare details structure of new drug price negotiation program

          MedicareonFridayreleasednewdetailsabouthowitsnewdrugpricenegotiationprogramwillwork,justtwomonthsbef

          read more
          With FDA staff opposed to Sarepta therapy, top official intervened
          With FDA staff opposed to Sarepta therapy, top official intervened

          AlogosignoutsideoftheheadquartersofSareptaTherapeuticsinCambridge,Mass.KristofferTripplaar/SipaviaAP

          read more
          Psychedelics group wrestles with new pharma identity
          Psychedelics group wrestles with new pharma identity

          OliviaGoldhill/STATDENVER—Hecouldhavebeenarockstar,areligiousicon,thewayecstaticapplausefromthousand

          read more

          Paxlovid study fails to answer questions over benefit for broader groups

          KobiWolf/BloombergPfizersaidTuesdaythatamuch-watchedstudyofitsantiviralPaxlovidinpatientswhohaveCovi